Barry S. Renaler, PhD
This content is PDF only. Please click on the PDF icon to access.
To the editors: By focusing exclusively on the early administration of zidovudine to persons who are positive for the human immunodeficiency virus (HIV), Ruedy and colleagues (1) in their recent editorial imply that this approach represents the only viable intervention strategy to delay the development of HIV-associated disease. This position appears to be at variance with well-documented interactions among infectious disease, nutritional status, and immune function (2). Infectious diseases influence the host's nutritional status and vice versa, and both factors significantly affect immune function. Even marginal deficiencies of single nutrients can severely impair immunologic processes and thereby alter the disease
Renaler BS. AIDS, Nutrition, and Infection. Ann Intern Med. ;113:409–410. doi: 10.7326/0003-4819-113-5-409_2
Download citation file:
Published: Ann Intern Med. 1990;113(5):409-410.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use